One To Watch

Achieve Life Science

A clinical-stage biopharmaceutical company developing cytisinicline, a plant-derived partial nicotinic receptor agonist, as a next-generation treatment for nicotine addiction and smoking cessation.

Company Overview

A clinical-stage biopharmaceutical company developing cytisinicline, a plant-derived partial nicotinic receptor agonist, as a next-generation treatment for nicotine addiction and smoking cessation. Achieve Life Sciences holds exclusive global rights to cytisinicline and is advancing it through late-stage clinical development toward FDA approval. The company's singular focus on nicotine dependence positions it within a large, commercially underserved therapeutic category where existing options show modest long-term quit rates.

Headquarters and Global Presence

Achieve Life Sciences is headquartered in Seattle, Washington. The company conducts clinical operations across North American trial sites and has pursued regulatory interactions primarily with the FDA as its lead market authority.

Founding and History

Achieve Life Sciences was founded to advance cytisinicline, a compound with decades of use in Eastern Europe as a smoking cessation aid, into the regulated Western pharmaceutical market. The company emerged from a reverse merger with OncoGenex Pharmaceuticals, announced in June 2024, which provided a public listing vehicle and additional financing runway. In April 2026, the company announced new leadership and a fresh financing round, signaling a strategic reset ahead of anticipated regulatory milestones.

Therapy Areas and Focus

The company is entirely focused on nicotine addiction, specifically cigarette smoking cessation in adult smokers. Smoking remains the leading cause of preventable death globally, yet approved pharmacotherapies — varenicline and bupropion — leave the majority of patients unable to achieve sustained abstinence. Achieve targets this gap with a compound that has a differentiated mechanism and a decades-long real-world safety record in Eastern European markets.

Technology Platforms and Modalities

Cytisinicline is a naturally occurring alkaloid extracted from the seeds of Cytisus laborinum L. (golden rain tree) and acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor — the same receptor targeted by varenicline. Its partial agonism reduces cravings and withdrawal symptoms while blunting the reinforcing effect of nicotine. Because cytisinicline has been used clinically in Central and Eastern Europe for over 50 years, its human safety profile is extensively characterized, potentially de-risking late-stage development.

Key Pipeline and Programs

**Cytisinicline — Smoking Cessation (Phase III):** Cytisinicline is the company's sole and lead asset, evaluated in two pivotal Phase III trials — ORCA-2 and ORCA-3. ORCA-2 assessed cytisinicline at 3 mg three times daily over a 12-week treatment course, with continuous abstinence rates as the primary endpoint. Results from the ORCA program demonstrated statistically significant and clinically meaningful improvements in quit rates versus placebo across multiple treatment durations. The company has engaged the FDA in discussions regarding a potential New Drug Application (NDA) submission pathway, with the ORCA data package forming the evidentiary foundation. A 25-day short-course formulation has also been explored to broaden patient access and prescriber flexibility, potentially differentiating cytisinicline from the standard 12-week varenicline regimen.

Recent Developments

The reverse merger between Achieve Life Sciences and OncoGenex Pharmaceuticals was announced in June 2024, with OncoGenex shares surging more than 50% in pre-market trading on the news. The deal provided Achieve with public company status and capital to advance its NDA preparations. In April 2026, the company announced new leadership appointments and a financing transaction, suggesting a recapitalization effort timed to support regulatory and commercial activities ahead of a potential NDA filing.

Key Personnel

Following the April 2026 leadership transition, new executive appointments were made to steer the company through its NDA filing phase and beyond; specific names were not disclosed in available announcements at time of publication. Previously, John Bencich served as Chief Financial Officer and Anthony Clarke as Executive Chairman, providing oversight of the reverse merger process. The board refresh reflects the company's shift from late-stage clinical execution toward regulatory and pre-commercial planning.

Strategic Partnerships

Achieve Life Sciences holds exclusive worldwide rights to cytisinicline, having licensed the compound for development in regulated Western markets. The reverse merger with OncoGenex, completed in 2024, effectively served as a financing and public listing mechanism rather than a traditional commercial partnership. No major big-pharma co-development or commercialization partnerships have been publicly disclosed to date, leaving the company pursuing an independent NDA pathway.

FAQ Section

The reverse merger with OncoGenex, announced in June 2024, offered Achieve a faster and more cost-efficient route to a public listing compared to a traditional IPO, which is particularly advantageous for a capital-intensive clinical-stage company. OncoGenex provided the listed shell structure while Achieve contributed its cytisinicline pipeline and clinical data, with the deal generating immediate investor interest — OncoGenex shares rose more than 50% in pre-market trading on the announcement. The subsequent April 2026 financing round suggests the combined entity has continued to access capital markets to fund regulatory milestones.

Cytisinicline acts as a partial agonist at the α4β2 nicotinic acetylcholine receptor, the primary neurobiological target mediating nicotine dependence. By binding this receptor with lower intrinsic efficacy than nicotine itself, it reduces dopaminergic reward from smoking while simultaneously dampening withdrawal symptoms and cravings. This dual effect mirrors the mechanism of varenicline (Chantix/Champix) but with a distinct molecular structure and a natural origin, offering a potential safety and tolerability differentiation point.

Cytisinicline shares varenicline's α4β2 partial agonist mechanism but benefits from more than five decades of clinical use in Central and Eastern Europe, providing an extensive real-world human safety dataset that most novel compounds lack at the NDA stage. Its natural alkaloid origin and distinct chemical structure mean it is not subject to varenicline's patent estate, and Achieve has explored a 25-day short-course dosing regimen alongside the standard 12-week course — a flexibility that could broaden prescriber uptake. The long Eastern European track record also potentially reduces regulatory uncertainty around safety signaling.

The ORCA Phase III program, comprising the ORCA-2 and ORCA-3 pivotal trials, demonstrated statistically significant improvements in continuous abstinence rates versus placebo for cytisinicline-treated adult smokers. The trials evaluated a 3 mg three-times-daily dosing schedule across 12-week treatment durations, with abstinence confirmed by carbon monoxide breath testing. The data package from the ORCA program forms the core of Achieve's planned NDA submission to the FDA and represents the company's primary value-inflection asset.

Achieve operates with a single-asset, single-indication strategy — cytisinicline for nicotine addiction and smoking cessation. Smoking cessation is a large and commercially proven category, with the global smoking cessation market estimated in the billions of dollars annually. The company's focused approach concentrates all R&D and regulatory resources on achieving FDA approval for cytisinicline rather than diversifying into adjacent indications, at least at this stage of development.

Achieve has completed its pivotal Phase III ORCA program and is in active FDA engagement regarding an NDA submission pathway, placing it at the late regulatory stage of development. The April 2026 leadership transition and financing round suggest the company is aligning its organizational and capital structure for the NDA filing and, potentially, pre-commercial build-out. A Prescription Drug User Fee Act (PDUFA) action date would follow NDA acceptance, making the filing timeline the single most important near-term milestone for investors and stakeholders.

Key watchpoints for Achieve Life Sciences include:

Want to Update your Company's Profile?